Scientech Research LLC Takes $97,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Scientech Research LLC acquired a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the second quarter, Holdings Channel.com reports. The fund acquired 43,350 shares of the company’s stock, valued at approximately $97,000.

A number of other institutional investors have also modified their holdings of TSHA. Principal Financial Group Inc. acquired a new stake in shares of Taysha Gene Therapies in the second quarter valued at $48,000. Cannon Global Investment Management LLC acquired a new stake in shares of Taysha Gene Therapies in the first quarter valued at $69,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Taysha Gene Therapies by 66.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 35,908 shares of the company’s stock valued at $103,000 after buying an additional 14,286 shares in the last quarter. Privium Fund Management B.V. acquired a new stake in shares of Taysha Gene Therapies in the second quarter valued at $213,000. Finally, Chicago Partners Investment Group LLC grew its stake in shares of Taysha Gene Therapies by 21.4% in the fourth quarter. Chicago Partners Investment Group LLC now owns 134,851 shares of the company’s stock valued at $239,000 after buying an additional 23,740 shares in the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Stock Up 0.5 %

Shares of NASDAQ TSHA opened at $2.02 on Wednesday. The company has a market capitalization of $413.98 million, a price-to-earnings ratio of -4.12 and a beta of 0.41. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22. The business has a 50-day moving average of $2.17 and a two-hundred day moving average of $2.57. Taysha Gene Therapies, Inc. has a 1 year low of $1.27 and a 1 year high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $1.11 million during the quarter, compared to the consensus estimate of $3.62 million. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. During the same period in the previous year, the business earned ($0.38) EPS. On average, analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TSHA has been the subject of several analyst reports. Piper Sandler lowered their target price on Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating for the company in a research note on Monday, July 1st. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Canaccord Genuity Group lowered their target price on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. Needham & Company LLC lowered their target price on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Finally, BMO Capital Markets initiated coverage on Taysha Gene Therapies in a research note on Thursday, June 27th. They set an “outperform” rating and a $5.00 target price for the company. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $6.38.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.